Revitope Oncology, Inc. — Form D/A
Revitope Oncology, Inc. of SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2016-09-14. The offering totals $8.2M, of which $8.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2016-09-14
- Form: D/A
- Accession: 0001140361-16-079736
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.2M
- Amount sold: $8.2M
- Investors: 12
- Date of first sale: 2016-02-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-257799
Issuer
- Name: Revitope Oncology, Inc.
- CIK: 0001667518
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 953 Indiana St, SAN FRANCISCO, CA, 94107
- Phone: (415) 710-6702
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Andrew Allen | Director | Atlanta, GA |
| Julie Cherrington | Director | San Francisco, CA |
| Mark Cobbold | Director | Pembroke, MA |
| Peter Joost | Director | San Francisco, CA |
| Raj Mehta | Director | Greenwich, CT |
| Andrew Allen | Executive Officer | Atlanta, GA |
| Julie Cherrington | Executive Officer | San Francisco, CA |
Other filings by this issuer (1)
More